Understanding PD-L1 Expression in Breast Cancer

PD-L1 (Programmed Death-Ligand 1) is a checkpoint protein expressed on tumor and immune cells. High PD-L1 expression indicates immune "cold" tumors evading immune surveillance and predicts response to checkpoint immunotherapy.

Prevalence and significance: ~40-50% of breast cancers express PD-L1. Particularly enriched in triple-negative breast cancer (~40-50%) and HER2-positive disease. PD-L1+ status predicts benefit from checkpoint inhibitors (anti-PD-1, anti-PD-L1).

Standard treatment with immunotherapy:

PD-L1 Testing and Assessment

PD-L1 testing is increasingly standard, especially in aggressive subtypes. Expression level predicts immunotherapy response:

PD-L1 High (≥1-50%)
Checkpoint-responsive
Higher expression predicts best response to checkpoint immunotherapy. Enriched trials for PD-L1+ patients. FDA-approved checkpoint inhibitor combinations indicated for this cohort.
PD-L1 Low/Negative
Limited checkpoint response
Lower expression predicts reduced immunotherapy benefit alone. May still respond to combinations (chemotherapy + immunotherapy) or other strategies. Emerging trials test converting immune-cold to immune-hot tumors.
Immune Infiltration Score
Prognostic factor
Beyond PD-L1: T-cell infiltration and immune microenvironment influence immunotherapy response. High immune infiltration predicts better checkpoint immunotherapy response; emerging tests quantify this.

PD-L1 Status and Treatment Strategy

Checkpoint immunotherapy mechanisms: Anti-PD-1 (pembrolizumab, nivolumab) or anti-PD-L1 (atezolizumab, durvalumab) antibodies block the PD-L1/PD-1 interaction, unleashing T-cell killing of tumor cells.

Subtype-specific implications:

Combination strategies: Trials increasingly test checkpoint inhibitors combined with other agents: chemotherapy (FDA-approved for many combinations), anti-HER2 therapy (for HER2+), hormone therapy (for HR+), or PARP inhibitors (for BRCA+).

Emerging approaches: Trials testing dual checkpoint inhibition (anti-PD-1 + anti-CTLA-4), checkpoint inhibitor combinations, and biomarker-guided selection beyond PD-L1 (tumor mutational burden, immune signatures).

Ready to explore PD-L1 breast cancer trials matching your profile?

Upload your pathology report, PD-L1 test results, and treatment history. We'll match you to recruiting trials and explain your eligibility for each.

PD-L1 Expression & Breast Cancer Trials

PD-L1 (Programmed Death-Ligand 1) is a checkpoint protein that helps tumors hide from immune attack by binding to PD-1 receptors on T cells, "turning off" immune surveillance.

Clinical significance: High PD-L1 expression indicates a tumor using this immune evasion mechanism. Checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) block this signal, reactivating immune attack. PD-L1+ breast cancers respond well to checkpoint immunotherapy, with FDA-approved combinations now standard in metastatic and early-stage disease.

PD-L1 testing: Immunohistochemistry (IHC) on tumor tissue. Results reported as percentage of tumor cells with PD-L1 expression (0%, 1-50%, >50%) or combined positive score (tumor cells + immune cells).

Results interpretation:

  • PD-L1 High (≥1-50%): Predicts good response to checkpoint immunotherapy. Qualifies for FDA-approved checkpoint inhibitor trials.
  • PD-L1 Low/Negative (0%): Lower expected checkpoint immunotherapy response but still may benefit from combinations or emerging approaches.

Some trials use different PD-L1 cutoffs — clarify with your oncologist what your specific result means for trial eligibility.

Pembrolizumab (Keytruda): Anti-PD-1 antibody. FDA-approved for PD-L1+ metastatic triple-negative breast cancer (combined with chemotherapy). Also approved in early-stage disease (with chemotherapy as neoadjuvant/adjuvant therapy).

Atezolizumab (Tecentriq): Anti-PD-L1 antibody. FDA-approved for PD-L1+ metastatic triple-negative breast cancer combined with chemotherapy and Abraxane (albumin-bound paclitaxel).

Evolving landscape: Additional checkpoint inhibitors (durvalumab, nivolumab, avelumab) in trials for breast cancer. Dual checkpoint inhibition (anti-PD-1 + anti-CTLA-4) under investigation.

Sometimes, depending on trial design. Many early trials enriched for PD-L1+ patients, but emerging data show:

Checkpoint + chemotherapy: Even PD-L1- tumors respond better to checkpoint + chemotherapy vs chemotherapy alone. Some trials now open to all patients regardless of PD-L1 status.

Combination approaches: PD-L1- tumors may respond better to checkpoint inhibitors combined with other agents (chemotherapy, anti-HER2, hormone therapy) than checkpoint monotherapy.

Biomarker alternatives: Emerging trials use tumor mutational burden (TMB) or immune infiltration scores rather than PD-L1 to predict response.

Discuss with your oncologist — PD-L1 negative status doesn't exclude checkpoint immunotherapy trials, especially in combination.

Checkpoint immunotherapy side effects: Caused by immune activation (different from traditional chemotherapy toxicity). Most common:

  • Fatigue (30-40%)
  • Rash (20-30%)
  • Diarrhea (20-30%)
  • Pneumonitis (1-5%, can be serious)
  • Colitis, hepatitis (rare but serious)
  • Thyroid dysfunction (5-10%)

Management: Most side effects manageable with steroids or supportive care. Serious immune-related adverse events (irAEs) require hospitalization and close monitoring.

Your trial team will monitor closely and manage side effects. Discuss with your oncologist before enrolling in a checkpoint trial.

Typically:

(1) Pathology report with PD-L1 testing results and interpretation (percentage, combined positive score).

(2) Cancer subtype information: ER/PR/HER2 status, grade, and if available, tumor mutational burden or other immune biomarkers.

(3) Imaging reports (CT, MRI, bone scan) showing disease extent and metastases.

(4) Prior treatment history with dates, agents, and response to chemotherapy/immunotherapy (if previously treated).

(5) ECOG performance status from your oncologist (0-2 scale).

(6) Recent blood work (CBC, liver/kidney function, immune cell counts — important for immunotherapy monitoring).